What is Pal-AHK?
Pal-AHK is a palmitoylated form of the tripeptide Ala-His-Lys used in cosmetic and hair-support discussions. Palmitoylation is intended to improve topical compatibility and skin or follicle delivery. [1][2]
The key public evidence comes from AHK and copper-complex hair-follicle biology rather than large finished-product clinical trials for every Pal-AHK cosmetic formula. [1][2]
Pal-AHK needs distinction from AHK-Cu, GHK-Cu, and Pal-GHK. Related copper-peptide biology can help explain plausibility, but each molecule and formulation has its own evidence limits. [1][2]
What Pal-AHK is investigated for
Pal-AHK evidence is grouped by practical use case and topical route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Hair growth and dermal papilla cell proliferation
Topical
Hair growth and dermal papilla cell proliferation
Topical
Hair growth is the most direct Pal-AHK signal, but it remains in vitro and preclinical. [1]
Hair follicle cell survival signaling
Topical
Hair follicle cell survival signaling
Topical
Hair follicle survival is a lower-confidence mechanism within hair support. [1]
Evidence snapshot
Overall confidence
Pal-AHK remains a preclinical-to-ex vivo cosmetic and hair-follicle rationale. Controlled finished-product scalp and skin outcomes remain limited. [1]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Human ex vivo hair-follicle work supports AHK-related plausibility, but controlled finished-product outcomes are limited. [1]
Animal / preclinical
Dermal papilla and follicle biology support the scalp rationale. [1]
Mechanism support
AHK-related tripeptide research links hair-follicle elongation, dermal papilla activity, and matrix signaling with scalp-support rationale. Palmitoylation is intended to make the peptide more formulation-friendly. [1]
Forms & administration
Pal-AHK is tracked as a topical cosmetic peptide ingredient for scalp and skin products. Its protocol context stays topical and formulation-specific rather than systemic. [2][1]
Dosing & protocols
The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.
Typical Range
Topical Pal-AHK products use formulation-specific cosmetic concentrations and application amounts rather than an injectable mg or mcg range. [2][1]
Frequency
Finished topical products commonly use once- or twice-daily application depending on the scalp or skin routine. [2][1]
Timing Considerations
Morning or evening routine timing is flexible; consistency and irritation control matter more than clock time. [2][1]
Cycle Length
Cosmetic scalp or skin comparisons usually need several hair-cycle or skin-turnover windows before the routine is changed. [2][1]
What to expect
First week
Topical Pal-AHK may change scalp or skin feel, surface smoothness, hydration, and comfort as the routine settles in. [1][2]
Weeks 8-12
Topical scalp or skin use may show changes in shedding, part-line appearance, texture, and skin smoothness in baseline photos. [1][2]
After stopping
Surface cosmetic effects may fade after topical Pal-AHK stops, and hair-cycle changes may drift gradually. [1][2]
Safety profile
Pal-AHK safety is mainly topical cosmetic tolerability: scalp sensitivity, irritation, dryness, formula concentration, and combinations with other actives matter. [1][2]
Who Pal-AHK is not for
Route-specific avoid and medical-review notes:
Drug & supplement interactions
Documented interactions are separated from theoretical or route-specific cautions.
Theoretical interactions
- Retinoids / acids / exfoliants
Retinoids, AHAs, BHAs, scrubs, or irritating scalp actives can compound redness, burning, and barrier disruption; this is a route-specific caution. [1][2]
- Other copper peptides
GHK-Cu, AHK-Cu, or multiple copper-peptide products can add copper-burden and irritation uncertainty; this is a product-quality caution. [1][2]
- Minoxidil / topical hair products
Minoxidil, alcohol-heavy vehicles, or leave-on hair actives can compound scalp dryness, itch, or irritation; this is a route-specific caution. [1][2]
Regulatory status
United States
In the U.S. as of 2026-06-21, Pal-AHK may appear in cosmetic-style topical products, but hair-growth or therapeutic claims are drug claims and are not FDA-approved. Cosmetic availability is not the same as drug approval. [2][3][6][7]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Topical | Not Approved Pal-AHK is not FDA-approved as a topical drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [2][3][6][7] | Not Listed Pal-AHK is not in the current reviewed 503A compounding bucket for the topical route; compounding status is separate from FDA drug approval. [2][3][6][7] |
Topical
International
EU/Europe, UK, Canada, and Australia separate cosmetic products from therapeutic claims. Topical cosmetic availability can follow cosmetic or industrial-chemical frameworks, while hair-growth, skin-lightening, injectable, oral, or disease-treatment claims need market-specific therapeutic-product review. [9][10][11][12][5][13][14][15][16]
Sports & competition
WADA has no specific issue for topical cosmetic Pal-AHK in the reviewed materials; S0 is mainly relevant if a product is used as a non-approved systemic pharmacological substance. [4][2][3][6][7]
How it works
Pal-AHK is built around an AHK-related tripeptide signal linked with hair-follicle elongation, dermal papilla activity, and extracellular-matrix signaling. In plain terms, the proposed cosmetic mechanism is local scalp or skin support. [1]
Topical delivery is the evidence boundary. Palmitoylation is meant to make the peptide more formulation-friendly, but a serum can only support a local cosmetic claim if the molecule reaches the target tissue at a concentration that matches the evidence. That keeps the mechanism local, cosmetic, and formulation-dependent rather than systemic. [1]
Research gaps & open questions
What the current literature has not yet settled about Pal-AHK:
Common questions
Is Pal-AHK a copper peptide?
Is Pal-AHK FDA-approved for hair growth?
Myths & misconceptions
History & discovery
Pal-AHK grew from cosmetic peptide attempts to adapt short hair- and matrix-related sequences for topical products. Its history is formulation-led, not systemic drug development. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2]
Human hair-follicle work on an AHK/copper-related tripeptide complex gave the family a scalp-support rationale. That evidence remains local and experimental rather than a drug approval path. [1][2]
Palmitoylation made AHK-style peptides more product-friendly for serums and cosmetic formulas. That shifted interpretation toward topical delivery, concentration, and vehicle rather than injectable outcomes. [1][2]
4 studies
The effect of tripeptide-copper complex on human hair growth in vitro.
Arch Pharm Res, 2007 Jul. in vitro.
Drugs@FDA/openFDA query for Pal-AHK
U.S. Food and Drug Administration. database query.
Compounding and the FDA: Questions and Answers
U.S. Food and Drug Administration. official guidance.
The 2026 List of Prohibited Substances and Methods
World Anti-Doping Agency. regulatory.